Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT05598437 Recruiting - Dry Eye Syndromes Clinical Trials

Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients

Start date: November 1, 2022
Phase:
Study type: Observational

Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed with Dry Eye

NCT ID: NCT05597397 Recruiting - Myopia Clinical Trials

Effect of Repeated Low-Level Red-Light Therapy on Retinal Function and Structure

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to evaluate the effect of repeated low-level red-light (RLRL) therapy on the retinal function and structure among myopic teenagers.

NCT ID: NCT05573984 Recruiting - Clinical trials for Retinitis Pigmentosa

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Start date: July 7, 2022
Phase:
Study type: Observational

The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.

NCT ID: NCT05553561 Recruiting - Dry Eye Disease Clinical Trials

Intense Regulated Pulse Light Therapy in Dry Eye Disease

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to assess the effect of intense regulated pulse light (IRPL) on the treatment of Dry eye.

NCT ID: NCT05524571 Recruiting - Thyroid Eye Disease Clinical Trials

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Start date: January 5, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

NCT ID: NCT05517447 Recruiting - Thyroid Eye Disease Clinical Trials

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Start date: November 6, 2023
Phase: Phase 3
Study type: Interventional

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

NCT ID: NCT05517421 Recruiting - Thyroid Eye Disease Clinical Trials

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Start date: November 23, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

NCT ID: NCT05514041 Recruiting - Dry Eye Disease Clinical Trials

A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

TSUNAMI
Start date: August 29, 2022
Phase: Phase 4
Study type: Interventional

A randomized, controlled, double-masked, investigator-initiated trial to evaluate tear film quality and stability in subjects with dry eye disease using OC-01 (varenicline solution) nasal spray 0.03 mg as compared to vehicle control nasal spray.

NCT ID: NCT05469932 Recruiting - Dry Eye Syndromes Clinical Trials

Quantum Molecular Resonance Effects on Patients With Dry Eye Disease

Start date: February 14, 2021
Phase: N/A
Study type: Interventional

The Rexon Eye device (Resono Ophthalmic Inc, Trieste, Italy) is a new device based on QMR technology. Quantum Molecular Resonance (QMR) is a technique in which low-intensity, high-frequency electric currents are administered to a biological tissue through contact electrodes. The device applies stimulation to the epidermis of closed eyelids up to the lid margin by means of specially designed goggles. Previous studies have shown that it is relatively safe with high patient satisfaction. Preliminary studies have also shown it is effective for accelerating healing in chronic wounds and treating dry eye symptoms.

NCT ID: NCT05414994 Recruiting - Clinical trials for Microbial Colonization

Assessment of the Ocular Microbiome in Health and Disease

Start date: September 7, 2023
Phase:
Study type: Observational

The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a longitudinal analysis of the ocular microbiome in adults.